ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.
- NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S.
- 10/14/2024
|
Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump
- U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.8% on Monday.
- 10/14/2024
|
S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise
- The S&P 500 rose to a new record high of 5,859 on Monday ahead of key corporate earnings later this week. At the time of writing, the S&P 500 index was 0.8% higher than the previous close.
- 10/14/2024
|
Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company
- H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
- 10/14/2024
|
Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.
- Longboard shareholders will be offered $60 per share in cash.
- 10/14/2024
|
LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) to H. Lundbeck A/S for $60.00 per share in cash share is fair to Longboard shareholders. Halper Sadeh encourages Longboard shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns.
- 10/14/2024
|
Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Longboard (NASDAQ: LBPH) for possible breaches of fiduciary duty and other violations of law in its transaction with Lundbeck. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. In the transaction, Longboard shareholders will receive only $60.00 per share in a tender offer that values the Longboard at approximately $2.6 billion equity value. The transaction.
- 10/14/2024
|
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
- VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash. The transaction is valued at approximately USD 2.6 billion equity value and USD.
- 10/14/2024
|
Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data
- Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussi {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"GuruFocus.com","item":"https://www.gurufocus.com"},{"@type":"ListItem","position":2,"name":"Latest News","item":"https://www.gurufocus.com/latest-news"},{"@type":"ListItem","position":3,"name":"U.S.","item":"https://www.gurufocus.com/latest-news/usa"},{"@type":"ListItem","position":4,"name":"Biotechnology","item":"https://www.gurufocus.com/latest-news/usa/biotechnology"},{"@type":"ListItem","position":5,"name":"NAS:LBPH","item":"https://www.gurufocus.
- 10/09/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 56,000 shares of its common stock (the “Common Stock”) and 35,000 restricted.
- 10/04/2024
|
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp SEA Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Dravet syndrome in participants two years of age and older. “We are thrilled to announce the initiation of our global Phase 3.
- 09/26/2024
|
Longboard Stock Soars on FDA Designations for Epilepsy Drug
- The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
- 09/20/2024
|
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event which will feature updates for the planned global Phase 3 Program evaluating bexicaserin (LP352), a first-in-class 5-HT2C receptor superagonist in development for the treatment of seizures associated with Developmental and Epi.
- 08/26/2024
|
Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript
- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securities Joel Beatty - Baird Gavin Clark-Gartner - Evercore Kalpit Patel - B. Riley Securities David Hoang - Citigroup Yatin Suneja - Guggenheim Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceuticals Earnings and Corporate Update Call.
- 08/04/2024
|
Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported second quarter 2024 financial results. “The first half of the year has been monumental for Longboard and underpins the vision that we have been working towards since the inception of the Company, which is to help a broad range of patients living.
- 08/01/2024
|
Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a con.
- 07/29/2024
|
Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 07/25/2024
|
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
- Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.
- 07/23/2024
|
Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet
- The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 07/09/2024
|
Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
- If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- 07/09/2024
|
Top 3 Health Care Stocks That May Crash This Quarter
- As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
- 07/03/2024
|
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
- Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
- 07/02/2024
|
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. “We are thrilled to receive Breakthroug.
- 07/01/2024
|
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #5HT2--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies. “We are thrilled to see a sustained, durable response in seizure.
- 06/10/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 92,000 shares of its common stock (the “Common Stock”) as inducements materia.
- 06/03/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 178,000 shares of its common stock (the “Common Stock”) as inducements mater.
- 05/06/2024
|
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results. “I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin.
- 05/02/2024
|
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard's Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN.
- 04/03/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 99,500 shares of its common stock (the “Common Stock”) as inducements materi.
- 04/02/2024
|
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
- LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results. “I am extremely proud of what our team has accomplished starting with the immense effort that went into the PACIFIC Study in participants with DEEs. We are impressed with the data in this study showing evidence.
- 03/12/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 184,000 shares of its common stock (the “Common Stock”) as inducements materi.
- 03/01/2024
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees. The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 145,475 shares of its common stock (the “Common Stock”) as inducements materi.
- 02/02/2024
|
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February. Conference Details: Event: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Details: Presenting in a fireside chat format on Wednesday, February 7, 2024, a.
- 02/01/2024
|
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares.
- 01/08/2024
|
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
- Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 01/05/2024
|
This biotech stock has surged over 300% this week
- As the market continues to witness a resurgence in small-cap investments, led by a jump in investor optimism and speculation, there's been a seemingly steady flow of capital back into traditionally riskier sectors.
- 01/05/2024
|
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offeri.
- 01/03/2024
|
Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study
- Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.
- 01/03/2024
|
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $150 million of shares of its voting common stock. In connection with the proposed offering, Longboard expects to grant the underwriters a 30-day option to purchas.
- 01/02/2024
|
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
- Clinical-stage biopharmaceutical firm Longboard Pharmaceuticals (NASDAQ: LBPH ) got the new year off to the best start possible with a dramatic run. Earlier Tuesday morning, management disclosed positive topline data for its therapeutic bexicaserin, which addresses seizures in patients with developmental and epileptic encephalopathies (DEEs).
- 01/02/2024
|
Longboard Pharmaceuticals stock soars on seizure drug results
- Longboard Pharmaceuticals Inc shares surged 181% to $16.96 in late-morning trading on Tuesday after the clinical-stage biopharmaceutical company revealed positive topline data from its PACIFIC Study evaluating bexicaserin, which reduced seizures by 53.3% across a population of patients with developmental and epileptic encephalopathies (DEE). Longboard noted the phase 1b/2a study included 52 patients ages 12 to 65 years old with different seizure disorders, including Lennox-Gastaut syndrome and Dravet syndrome.
- 01/02/2024
|
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #DEEs--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). The PACIF.
- 01/02/2024
|
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-clas.
- 01/01/2024
|
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
- LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neur.
- 11/29/2023
|
Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)
- Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/24/2023
|
Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
- Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 05/01/2023
|
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
- Longboard Pharmaceuticals, Inc. (LBPH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 04/14/2023
|
Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect?
- The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to a 208.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 04/07/2023
|
Longboard Pharmaceuticals, Inc. (LBPH) Q4 2022 Results - Earnings Call Transcript
- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q4 2022 Results Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Neena Bitritto-Garg - Citigroup Global Markets Josh Schimmer - Evercore ISI Charles Duncan - Cantor Fitzgerald & Co. Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Patrick Trucchio - H.C. Wainwright & Co., LLC Operator Good day and thank you for standing by.
- 03/02/2023
|
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023
- SAN DIEGO--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day.
- 02/23/2023
|
Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar
- Shares have fallen by nearly 70% since IPO. Leadership including President & CEO hails from Arena Pharmaceuticals (bought out by Pfizer for $6.7B last year, which still owns 23% of Longboard).
- 11/23/2022
|
Longboard Pharmaceuticals to Present at Guggenheim's Healthcare Talks 4th Annual Immunology and Neurology Day
- LA JOLLA, Calif.
- 11/08/2022
|
Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
- SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the Citi Annual BioPharma Conference, which is taking place September 7-8, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022, in New York City.
- 09/01/2022
|
2 ‘strong buy' penny stocks with over 300% possible upside
- Penny stocks are shares usually below $5, representing small companies, most of which trade by over-the-counter (OTC) transactions, while there
- 08/19/2022
|
Longboard Pharmaceuticals to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
- SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard's Chief Financial Officer, will present as a panelist at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 12:35PM ET.
- 08/03/2022
|
Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15
- SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin Lind, Longboard's President & CEO, will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 3:00PM ET, in New York City.
- 06/07/2022
|
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
- SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that single ascending dose and multiple ascending dose data from the Phase 1 study evaluating LP352 in healthy volunteers will be presented at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7, 2022, in Seattle, WA, and virtually April 24–26, 2022.
- 04/01/2022
|
Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock Now
- Longboard Pharmaceuticals, Inc. (LBPH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 12/06/2021
|
Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
- SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Cantor Virtual Global Healthcare Conference on September 28, 2021.
- 09/21/2021
|
Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
- SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced today that the Company successfully completed the multiple ascending dose (MAD) portion of a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating doses of LP352, an oral, centrally acting, next-generation 5-HT2c receptor superagonist, in healthy volunteers. Longboard plans to advance LP352 into a Phase 1b/2a efficacy trial in adult participants with DEEs in the first quarter of 2022 in study sites across the United States.
- 09/08/2021
|
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
- SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
- 08/09/2021
|
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
- SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80.0 million.
- 03/11/2021
|
